Xeris Biopharma Holdings
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Illinois, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1375 W Fulton St Ste 1300, Chicago, Illi...Phone Number
(844) 445-5704Website
www.xerispharma.comRevenue
$314.9 MillionStock Symbol
XERSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
2
1
1
About Xeris Biopharma Holdings
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative therapies that address serious chronic and rare medical conditions. The company focuses on advancing pharmaceutical products that improve patient care by enhancing treatment convenience, expanding therapeutic options, and addressing unmet medical needs across multiple disease areas.Explore more
Xeris Biopharma Holdings Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xeris Biopharma Holdings your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Xeris Biopharma Holdings launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Xeris Biopharma Holdings
Check if Xeris Biopharma Holdings has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Xeris Biopharma Holdings has new funding data
Check out if Xeris Biopharma Holdings is spiking on competitors!
Click to see if Xeris Biopharma Holdings had a recent Job posting/layoffs
Earning: See what the market has to say on Xeris Biopharma Holdings recently announced quarterly report
Website visits: Recent activity has been detected on your website
Xeris Biopharma Holdings, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Xeris Biopharma Holdings
Find more new buyers
Compare Similar Companies to Xeris Biopharma Holdings
Compare insights from companies similar to Xeris Biopharma Holdings, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xeris Biopharma Holdings is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xeris Biopharma Holdings is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xeris Biopharma Holdings.
Xeris Biopharma Holdings financials insights
Gather financial insights about Xeris Biopharma Holdings, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$1.8M
2013
Debt
$2.3M
2014
Series B
$7.3M
2018
Series C
$81M
Stock Offering
$98.3M
2019
Stock Offering
$55.6M
Debt
$85M
2020
Multiple Rounds
$152.1M
2022
Share Placement
$30M
Debt
$150M
Xeris Biopharma Holdings Tech Stack
A closer look at the technologies used by Xeris Biopharma Holdings
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Hiring Plans
Xeris Biopharma has more open roles in Medical & Health than it has had at any time in the past 9 months.
Hiring Plans
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
Xeris Biopharma Holdings News & Media
Xeris Biopharma Q1 Earnings Call Highlights
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio. On the company’s earnings call, Chief Executive Officer John ShanXeris Biopharma Q4 Earnings Call Highlights
Xeris Biopharma (NASDAQ:XERS) reported sharp top-line growth in the fourth quarter and full year 2025, highlighted by what management described as a “defining milestone” for the company: financial self-sustainability. On its fourth quarter earnings call, executives also outlined a 2026 outlook calliWhy Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
One of the company's key drugs won't be challenged by a competing medication anytime soon.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xeris Biopharma Holdings
Sign Up For FreeTo access detailed company insights
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative therapies that address serious chronic and rare medical conditions. The company focuses on advancing pharmaceutical products that improve patient care by enhancing treatment convenience, expanding the... Read More
